Pharm Flashcards
risk factors for drug interactions
multiple medications female gender extremes of age major organ dysfunction genetic polymorphisms metabolic and endocrine dysfunction
pharmacokinetics
what body does to drug
pharmacodynamics
what drug does to body
additive
alcohol and benzo
antagonist
diazepam and flumazenil
caution with tobramycin
worsens respiratory depression in surgery
decrease Ach and interacts with succinylcholine
reverse with neostigmine
antacids
prevent absorption
interacts with tetracycline
cholestyramine
interacts with digoxin and warfarin
mycophenolate mofetil
interacts with ferrous sulfate, Ca, Mg, or Al
physical complex prevents absorption
not due to pH effect
shift in peak but not bioavailability
due to changes in GI motility
just changes rate of absorption
decreased gastric motility
decreased rate of absorption
amitriptyline, morphine
increases gastric motility
greater peak effect
metoclopramide
raises gastric pH
H2 antagonists and PPI
H2 antagonists decrease
ktoconazole and itraconazole
PPI decreases
atazanavir, itraconazole, and ketoconazole
p-glycoprotein
ATP dependent molecular transport
protects from harmful substances-out of brain, into gut, lumen, bile and urine
inhibitors p-glycoprotein
ketoconazole, erythromycin, grapefruit juice, clarithromycin
some are inhibitors of CYP3A
OCP and antibiotics
greater failure if taken with erythromycin
warfarin and SMX-TMP
warfarin usually 99% bound
SMX-TMP increase INR>6
cytochrome p450
present in ER
primarily phase I metabolism
inhibition p450
ketoconazole, cimetidine, erythromycin, grapefruit juice (furanocoumarins and naringin), and clarithromycin
induction p450
phenytoin, rifampin, carbamazepine, St. John Wort
CYP1A2-theophylline
induced by phenobarbital
CYP2C9-warfarin
induced by rifampin
inducer CYP3A4
phenytoin
inhibitor CYP3A4
erythromycin, ketoconazole
tamoxifen CYP2D6
less formation of active metabolite in slow metabolizers
CYP2C19 and clopidogrel
less effective in slow metabolizers
renal tubular secretion
drug compete for same transport
probenecid and penicillins
sulfa and MTX (increase MTX levels in blood)
altered tubular reabsorption
trimethoprim inhibits sodium channel in distal tubule results in increased K reabsorption (higher dose in pneumocystis)
lithium and diuretics leads to decreased lithium clearance
digoxin and quinidine
less digoxin renal excretion
p glycoprotein inhibitor
alterations in urine pH
non-ionized are reabsorbed
high pH causes basic to be unionized
low pH causes acidic to be unionized
acetazolamide and quinidine/amphetamines
increase urine pH
higher unionized quinidine-higher reabsorption
aspirin and acetazolamide
increase ASA toxicity
metabolic acidosis increase unionized ASA into brain
increase ASA filtered and reabsorbed by kidney
high potential macrolides
erythromycin and clarithromycin
high potential H2 blockers
cimetidine
high statins
lovastatin (prodrug) and atorvastatin
lethal dose
lower LD is more toxic
mechanism of carbon monoxide toxicity
binds ferrous iron to form carboxyHb
reduction in O2 carrying capacity
toxicity from anoxia
target of carbon monoxide
globus pallidus in cerebellum
mechanism of cyanide toxicity
mitochondrial toxin that inhibits ETC
binds ferric iron-inhibit electron transport between a and a3
symptoms cyanide toxicity
rapid progression
nausea, lightheadedness, hyperventilation, feelings of suffocation, convulsions, coma
increased HR followed by decreased
death from respiratory failure, brain damage in recovered
treatment cyanide toxicity
nitrite to converte hemoglobin to HbFe3
administer thiosulfate
mechanism of toxicity organophosphates
inhibit AchE
increase Ach levels and exaggerate effects of cholinergic
treatment for organophosphates
atropine and 2PAM
carbamates mechanism of toxicity
inhibits AchE but reactivates faster (half life 1 hr)
treatment for carbamate
atropine only
do not use 2PAM
symptoms paraquat
inhaled-acute irritation, pulmonary fibrosis
oral-irritation and ulceration of mucous membranes
dermal-erythema, ulceration, cataract formation
treatment paraquat
gastric lavage
kaolin-limited use
hemodialysis or hemoperfusion
qualitative test
paraquat
sodium dithionite in 2N sodium hydroxide forms blue color
acute toxicity benzene
CNS depression and/or pulmonary irritation/edema
chronic toxicity benzene
anemia, leukemia, lymphomas
acute toluene and xylene toxicity
CNS depression
standardized supplements
certain concentration is consistent between batches
NF
meets standard for purity, strength of marker compound and labeling
effects of garlic
lowers cholesterol
inhibits platelet aggregation
ingredients of garlic responsible for platelet aggregation
ajoene (allicin) and diallyl trisulfide
non-refrigerator chopped garlic
risk of c. diff if stored at room temperature
activity in horse chesnut
escin (good) and asesculin (adverse)
effect of escin in horse chesnut
reduces leg pain and swelling
decreases vascular permeability of venous capillaries
effect of aesculin
similar to warfarin
bleeding gums, nose
contraindications horse chesnut
anticoagulants, NSAIDs-enhance bleeding
pregnancy
breast feeding
standardized ginko
for quercetin, kaempferol, and isorhamnetine
effects kaempferol from ginko
anti-oxidant
improves ATP and glucose utilization
effects of kaempferol and apigenin
inhibitors of MAO-A and MAO-B
adverse effects of ginko
major bleeding
drug interactions-aspirin, NSAIDs, warfarin, heparin, clopidogrel
seizures and ingestion from lethal ingestion
interferes with amino acid metabolism
antivitamin B6
standardized St. John Wort
hypericin and hyperforin
serotonin re-uptake inhibitor
dependent on hyperforin content
MAO inhibition
hypericin and hyperforin
SSRI>MAOI
side effects St. John Wort
HA, loss of appetite
should not be taken with MAOI or SSRI
induces P450 cyp3A4
increase dose when on St. John Wort
OCP, theophylline, warfarin
active ingredient Valerian
valerenic acid, valtrate
glutamine
neural effects of valerian
bind GABA A open Cl
hyperpolarization
use echinacea
lessens symptoms of colds, flu, infections
e purpura
only aerial
e pallida
aerial and root active
e angustifolia
root
arabinogalactan
releases IL-1 TNFa
heteroxylan
stimulates PMN phagocytosis